Detalhe da pesquisa
1.
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Blood
; 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38662991
2.
Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update.
Blood
; 143(17): 1713-1725, 2024 Apr 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-38194692
3.
B-cell non-Hodgkin lymphomas.
Lancet
; 403(10438): 1791-1807, 2024 May 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38614113
4.
Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network.
Lancet
; 2024 May 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-38705160
5.
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma.
N Engl J Med
; 386(26): 2482-2494, 2022 06 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35657079
6.
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
N Engl J Med
; 386(7): 629-639, 2022 02 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904798
7.
Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse.
Blood
; 140(17): 1907-1916, 2022 10 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-35789260
8.
Genomic profiling for clinical decision making in lymphoid neoplasms.
Blood
; 140(21): 2193-2227, 2022 11 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36001803
9.
Rituximab, gemcitabine and oxaliplatin in relapsed or refractory indolent and mantle cell lymphoma: results of a multicenter phase I/II-study of the German Low Grade Lymphoma Study Group.
Ann Hematol
; 2024 Mar 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38459156
10.
Real-world experience among patients with relapsed/refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor failure in Europe: The SCHOLAR-2 retrospective chart review study.
Br J Haematol
; 202(4): 749-759, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36257914
11.
LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome.
Blood
; 137(23): 3251-3258, 2021 06 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-33513604
12.
CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
Blood
; 138(24): 2499-2513, 2021 12 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-34166502
13.
A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL.
Blood
; 137(19): 2646-2656, 2021 05 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-33512419
14.
Mantle cell lymphoma-Update on molecular biology, prognostication and treatment approaches.
Hematol Oncol
; 41 Suppl 1: 36-42, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37294961
15.
Combined treatment with crizotinib and temsirolimus is an effective strategy in mantle cell lymphoma and can overcome acquired resistance to temsirolimus.
Hematol Oncol
; 41(5): 858-868, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37300279
16.
The addition of rituximab to chemotherapy improves overall survival in mantle cell lymphoma-a pooled trials analysis.
Ann Hematol
; 102(10): 2791-2801, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37552322
17.
Long-term outcome in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
Eur J Haematol
; 111(2): 220-228, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37094812
18.
The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL.
Am J Hematol
; 98(11): 1699-1710, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37584447
19.
Treatment, outcome and re-vaccination of patients with SARS-CoV-2 vaccine-associated immune thrombocytopenia.
Infection
; 51(1): 231-238, 2023 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-36195695
20.
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial.
Br J Haematol
; 198(3): 482-491, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35362552